Skip to content

Study · Not a test of the peptide alone · 2008

4 results

Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: effect of cyclization on tumor-seeking properties.

Raposinho PD, Xavier C, Correia JD, Falcão S, Gomes P, Santos I

Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry8 Jan 2008Cited by 33 (Europe PMC)

PMID18183429 (opens in a new tab)DOI10.1007/s00775-007-0338-3 (opens in a new tab)PepBankPUB-18183429
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Pharmacokinetics

    In melanoma-bearing C57BL6 mice, the cyclic MT-II-based radioconjugate showed significant tumor uptake and retention, 9.26 and 11.31 %ID/g at 1 and 4 h after injection.

    In plain wordsIn mice with melanoma, a radiolabeled melanotan II-based compound built up in the tumor.

    Peptide
    Melanotan II
    Outcome
    Not applicableTumor uptake of cyclic radioconjugate
    Study

    mousen: not reported in source

    Melanoma-bearing C57BL6 mice
    Outcome group
    Pharmacokinetics · Cancer

    Measurements

    Tumor uptake
    9.26 %ID/g
    1 h after injection
    Tumor uptake
    11.31 %ID/g
    4 h after injection

    Source sentences

    Summary
    A significant tumor uptake and retention was obtained in melanoma-bearing C57BL6 mice for the cyclic radioconjugate [9.26 +/- 0.83 and 11.31 +/- 1.83% ID/g at 1 and 4 h after injection, respectively].
    1 context sentence
    Summary · context
    Taking advantage of the superior biological features associated with the MT-II cyclic peptide

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  2. 02AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In melanoma-bearing mice, receptor blocking with (Nle4,DPhe7)-alphaMSH reduced tumor uptake of the cyclic radioconjugate by 74.8% at 4 h, which showed MC1R specificity.

    In plain wordsIn mice with melanoma, blocking the receptor lowered tumor uptake of the radiolabeled compound, which shows it binds that receptor.

    Peptide
    Melanotan II
    Outcome
    DecreaseMC1R specificity by receptor blocking of cyclic radioconjugate
    Study

    mousen: not reported in source

    Melanoma-bearing C57BL6 mice
    Outcome group
    Diagnostic imaging · Cancer

    Measurements

    Reduction of tumor uptake
    74.8%
    cyclic radioconjugate, 4 h

    Source sentences

    Summary
    Receptor blocking studies with the potent (Nle4,DPhe7)-alphaMSH agonist demonstrated the specificity of the radioconjugates to MC1R (74.8 and 44.5% reduction of tumor uptake at 4 h after injection for cyclic and linear radioconjugates, respectively).
    1 context sentence
    Summary · context
    Taking advantage of the superior biological features associated with the MT-II cyclic peptide

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  3. 03LabNot a test of Melanotan II aloneIn vitro (cells)Activity measurement

    In murine B16F1 melanoma cells, the cyclic 99mTc(CO)3-labeled MT-II-based conjugate showed 87.1% internalization of receptor-bound tracer and 50.5% of total applied activity after 6 h at 37 degrees C.

    In plain wordsIn lab tests with mouse melanoma cells, a radiolabeled melanotan II-based compound was taken up strongly by the cells.

    Peptide
    Melanotan II
    Outcome
    Not applicableCellular internalization of cyclic 99mTc(CO)3-labeled conjugate
    Study

    mousen: not reported in source

    Murine melanoma B16F1 cells
    Outcome group
    Diagnostic imaging · Cancer

    Measurements

    Internalization of receptor-bound tracer
    87.1%
    6 h, 37 C
    Internalization of total applied activity
    50.5%
    6 h, 37 C

    Source sentences

    Summary
    The cyclic 99mTc(CO)3-labeled conjugate presents a remarkable internalization (87.1% of receptor-bound tracer and 50.5% of total applied activity, after 6 h at 37 degrees C)
    1 context sentence
    Summary · context
    Taking advantage of the superior biological features associated with the MT-II cyclic peptide

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  4. 04LabNot a test of Melanotan II aloneIn vitro (cells)Activity measurement

    In murine B16F1 melanoma cells, only 24.7% of the cyclic 99mTc(CO)3-labeled MT-II-based conjugate was released from the cells after 5 h.

    In plain wordsIn lab tests with mouse melanoma cells, a radiolabeled melanotan II-based compound stayed inside the cells, with little released.

    Peptide
    Melanotan II
    Outcome
    Not applicableCellular retention of cyclic 99mTc(CO)3-labeled conjugate
    Study

    mousen: not reported in source

    Murine melanoma B16F1 cells
    Outcome group
    Diagnostic imaging · Cancer

    Measurements

    Activity released from cells
    24.7%
    5 h

    Source sentences

    Summary
    and cellular retention (only 24.7% released from the cells after 5 h) in murine melanoma B16F1 cells
    1 context sentence
    Summary · context
    Taking advantage of the superior biological features associated with the MT-II cyclic peptide

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.